Get the Stockscreener App
0.65
0.75%
-0.0049
After Hours:
.68
0.03
+4.62%
Processa Pharmaceuticals Inc Stock (PCSA) Forecast
The Processa Pharmaceuticals Inc (PCSA) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $52.64, representing a +7,999% increase from the current price of $0.65. The highest analyst price target is $70.75, and the lowest is $34.54.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month PCSA Price Target
Average 57.64
(+8,767% Upside)
Is Processa Pharmaceuticals Inc (PCSA) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 35.60 | Neutral |
| STOCH(9,6) | 28.50 | Neutral |
| STOCHRSI(14) | 50.94 | Neutral |
| MACD(12,26) | -0.0929 | Sell |
| ADX(14) | 14.60 | Neutral |
| William %R | -59.27 | Neutral |
| CCI(14) | -52.33 | Neutral |
Buy: 0
Sell: 1
Neutral: 6
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
0.6746
Sell
|
0.6816
Sell
|
| MA20 |
0.7809
Sell
|
0.7549
Sell
|
| MA50 |
0.917
Sell
|
0.9067
Sell
|
| MA100 |
1.0952
Sell
|
2.1535
Sell
|
| MA200 |
1.4354
Sell
|
17.54
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, PCSA could be considered a Strong Sell, with 17 technical analysis indicators signaling 0 Buy signals, 11 signaling Sell signals and 6 Neutral signals. This might not be a good time to consider opening new positions on PCSA, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 35.6 indicates that PCSA is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 28.5 indicates that PCSA is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 50.94 indicates that PCSA is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 14.6 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -52.33 indicates that PCSA is still oversold but not to an extreme extent.
Long-term PCSA price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Processa Pharmaceuticals Inc financial reports and earnings history, Processa Pharmaceuticals Inc (PCSA) stock could reach $47.14 by 2030, $32.92 by 2040 and $291.65 by 2050. See the projected annual prices until 2050 of the Processa Pharmaceuticals Inc stock below:
- Processa Pharmaceuticals Inc (PCSA) is expected to reach an average price of $78.30 in 2035, with a high prediction of $77.93 and a low estimate of $77.89. This indicates an $11,946% rise from the last recorded price of $0.65.
- Processa Pharmaceuticals Inc (PCSA) stock is projected to chart a bullish course in 2040, with an average price target of $32.02, representing an $4,826% surge from its current level. The forecast ranges from a conservative $32.19 to a sky-high $32.92.
- Our analysts predict Processa Pharmaceuticals Inc (PCSA) to jump 46,676% by 2045, soaring from $303.66 to an average price of $304.04, potentially reaching $302.70. While $303.66 is the low estimate, the potential upside is significant.
- Processa Pharmaceuticals Inc (PCSA) stock is expected to climb by 2050, reaching an average of $301.05, a $46,215% jump from its current level. However, a wide range of estimates exists, with high and low targets of $291.65 and $301.09, respectively, highlighting the market's uncertainty.
Processa Pharmaceuticals Inc Stock (PCSA) Year by Year Forecast
Processa Pharmaceuticals Inc Stock (PCSA) Price Forecast for 2025
Processa Pharmaceuticals Inc Stock (PCSA) is expected to reach an average price of $59.61 in 2025, with a high prediction of $115.19 and a low estimate of $4.0321. This indicates an +9,071% rise from the last recorded price of $0.65.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| March, 2025 | $40.76 | $34.54 | $70.75 | +6,170% |
| April, 2025 | $92.37 | $42.96 | $92.37 | +14,111% |
| May, 2025 | $88.38 | $74.57 | $115.19 | +13,497% |
| June, 2025 | $76.39 | $63.39 | $101.18 | +11,653% |
| July, 2025 | $34.81 | $29.01 | $82.39 | +5,255% |
| August, 2025 | $39.02 | $17.30 | $49.82 | +5,903% |
| September, 2025 | $10.23 | $4.0321 | $46.62 | +1,474% |
| October, 2025 | $15.25 | $6.2439 | $34.24 | +2,246% |
| November, 2025 | $11.66 | $6.2586 | $30.85 | +1,694% |
| December, 2025 | $12.02 | $7.0645 | $28.07 | +1,749% |
Processa Pharmaceuticals Inc Stock (PCSA) Price Forecast for 2026
The predicted value for Processa Pharmaceuticals Inc (PCSA) in 2026 is set at an average of $15.65. Estimates vary from a peak of $31.22 to a trough of $0.0822, indicating an +2,308% surge from the present price of $0.65.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $13.91 | $0.0822 | $16.68 | +2,041% |
| February, 2026 | $10.78 | $1.0939 | $14.91 | +1,558% |
| March, 2026 | $9.3087 | $3.3028 | $24.50 | +1,332% |
| April, 2026 | $17.12 | $8.1146 | $31.22 | +2,534% |
| May, 2026 | $16.64 | $14.73 | $23.33 | +2,459% |
| June, 2026 | $3.947 | $1.447 | $18.94 | +507.22% |
| July, 2026 | $2.9617 | $1.4501 | $12.75 | +355.64% |
| August, 2026 | $4.5735 | $0.7646 | $12.94 | +603.61% |
| September, 2026 | $1.0582 | $0.6147 | $6.3764 | +62.80% |
| October, 2026 | $11.80 | $2.4089 | $9.60 | +1,715% |
| November, 2026 | $15.69 | $10.79 | $13.69 | +2,314% |
| December, 2026 | $17.38 | $16.97 | $16.38 | +2,573% |
Processa Pharmaceuticals Inc Stock (PCSA) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Processa Pharmaceuticals Inc (PCSA) is $9.7003, with a high forecast of $19.16 and a low forecast of $0.239. This indicates an +1,392% increase from the last price of $0.65.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $19.98 | $17.15 | $19.16 | +2,973% |
| February, 2027 | $16.94 | $17.94 | $18.27 | +2,506% |
| March, 2027 | $14.54 | $13.88 | $14.16 | +2,136% |
| April, 2027 | $13.89 | $12.12 | $12.41 | +2,037% |
| May, 2027 | $13.05 | $13.11 | $12.12 | +1,908% |
| June, 2027 | $12.30 | $12.42 | $12.33 | +1,792% |
| July, 2027 | $11.99 | $12.29 | $12.09 | +1,744% |
| August, 2027 | $12.07 | $12.47 | $11.28 | +1,757% |
| September, 2027 | $8.0386 | $8.8586 | $10.67 | +1,137% |
| October, 2027 | $4.0469 | $5.8469 | $7.2557 | +522.59% |
| November, 2027 | $2.4649 | $0.239 | $5.5649 | +279.22% |
| December, 2027 | $5.3203 | $4.5132 | $3.4753 | +718.51% |
Processa Pharmaceuticals Inc Stock (PCSA) Price Forecast for 2028
In 2028, Processa Pharmaceuticals Inc (PCSA) is projected to reach an average price of $65.12, with a high projection of $129.77 and a low estimate of $0.4792. This indicates an +9,919% rise from the last price of $0.65.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $5.7186 | $6.1186 | $5.8815 | +779.78% |
| February, 2028 | $4.1368 | $4.1868 | $5.1056 | +536.43% |
| March, 2028 | $1.792 | $2.332 | $3.5738 | +175.70% |
| April, 2028 | $0.7903 | $0.9903 | $2.0691 | +21.58% |
| May, 2028 | $84.14 | $0.4792 | $84.15 | +12,845% |
| June, 2028 | $29.12 | $38.32 | $60.54 | +4,380% |
| July, 2028 | $32.00 | $16.11 | $27.10 | +4,822% |
| August, 2028 | $25.07 | $32.08 | $27.17 | +3,756% |
| September, 2028 | $58.76 | $6.254 | $110.16 | +8,940% |
| October, 2028 | $64.58 | $50.26 | $129.77 | +9,836% |
| November, 2028 | $14.21 | $10.80 | $78.19 | +2,086% |
| December, 2028 | $23.17 | $16.20 | $17.42 | +3,464% |
Processa Pharmaceuticals Inc Stock (PCSA) Price Forecast for 2029
The 2029 price forecast for Processa Pharmaceuticals Inc Stock (PCSA) is $25.48 on average, with a high prediction of $50.57 and a low estimate of $0.3817. This represents an +3,820% increase from the previous price of $0.65.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $21.66 | $14.55 | $35.86 | +3,233% |
| February, 2029 | $1.0874 | $9.4756 | $31.07 | +67.30% |
| March, 2029 | $27.09 | $21.91 | $22.69 | +4,068% |
| April, 2029 | $16.33 | $1.4654 | $19.93 | +2,413% |
| May, 2029 | $24.16 | $6.1404 | $50.57 | +3,618% |
| June, 2029 | $13.79 | $0.3817 | $37.39 | +2,021% |
| July, 2029 | $12.79 | $6.5955 | $20.19 | +1,868% |
| August, 2029 | $19.96 | $21.36 | $17.77 | +2,971% |
| September, 2029 | $47.14 | $29.75 | $33.06 | +7,152% |
| October, 2029 | $40.11 | $40.32 | $39.13 | +6,070% |
| November, 2029 | $42.08 | $40.09 | $33.68 | +6,374% |
| December, 2029 | $36.66 | $44.66 | $42.67 | +5,540% |
Processa Pharmaceuticals Inc Stock (PCSA) Price Forecast for 2030
Processa Pharmaceuticals Inc Stock (PCSA) is expected to reach an average price of $35.61 in 2030, with a high forecast of $47.42 and a low forecast of $23.81. This signifies an +5,379% surge from the last price of $0.65.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $64.03 | $42.45 | $47.14 | +9,751% |
| February, 2030 | $37.73 | $46.01 | $47.42 | +5,704% |
| March, 2030 | $37.58 | $38.20 | $34.59 | +5,682% |
| April, 2030 | $17.56 | $23.81 | $30.58 | +2,601% |
| May, 2030 | $26.63 | $26.14 | $22.35 | +3,997% |
| June, 2030 | $37.71 | $32.52 | $27.32 | +5,701% |
| July, 2030 | $36.68 | $36.89 | $34.89 | +5,543% |
| August, 2030 | $33.45 | $34.46 | $32.66 | +5,047% |
| September, 2030 | $34.93 | $36.85 | $34.54 | +5,274% |
| October, 2030 | $46.20 | $38.02 | $44.00 | +7,008% |
| November, 2030 | $48.48 | $44.39 | $46.48 | +7,358% |
| December, 2030 | $48.35 | $48.55 | $46.18 | +7,339% |
3.95%
2.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):